Replies to post #274 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Encouraging data that caused the stock to rise ~8% https://www.globenewswire.com/news-release/2023/05/25/2676763/0/en/Cullinan-Oncology-to-Present-First-Monotherapy-Clinical-Data-for-CLN-619-a-Novel-Anti-MICA-B-Antibody-at-ASCO-2023.html

As for solids, NKTX could start by testing NKX101 in HCC, intrahepatic cholangiocarcinoma, and/or surgically resected CRC where only liver metastases remain via locoregional delivery.

Also, have a collaboration with CRSP to co-develop and co-commercialise two CAR-NK cell product candidates and another that will combine CAR-NK with CAR-T. The first candidate will a gene-edited NK cell targeting CD70 https://jitc.bmj.com/content/9/Suppl_2/A123 https://aacrjournals.org/cancerres/article/82/12_Supplement/5512/700598/Abstract-5512-CBLB-CISH-and-CD70-multiplexed-gene